Abstract：Objective To evaluate the efficacy and safety of 131I-Metuximab injection (Licartine) combined with hepatic artery transcatheter arterial chemoembolization (TACE) in the treatment of advanced primary liver cancer. Methods A total of 45 patients with advanced liver cancer who admitted to the Cancer Center of Renmin Hospital of Wuhan University from January 2017 to February 2019 were selected and divided into two groups according to the treatment method, 15 cases in group A, receiving licartin combined with TACE treatment; 30 cases in group B received TACE treatment alone. After treatment, patients of the two groups were followed up to observe, and the objective response rate (ORR), disease control rate (DCR), progress free survival (PFS) time, interventional treatment-related adverse reactions, hematological toxicity (white blood cell [WBC] count, platelet [PLT] count) and liver function damage [total bilirubin (TB), alanine transaminase (ALT)] rate were compared between the two groups. Results There were no significant differences in ORR, DCR and PFS between the two groups (all P ＞ 0.05). In terms of adverse reactions related to interventional therapy, there were no significant differences in the incidence of fever, abdominal pain, nausea and vomiting between the two groups (all P ＞ 0.05). In terms of hematological toxicity, the PLT count in group A was significantly lower than that in group B at one week after operation, and the difference was statistically significant (P ＜ 0.05). There was no statistically significant difference in WBC counts between the two groups at one week after surgery (P ＞ 0.05). In terms of liver function, there were no statistically significant differences in TB and ALT levels between the two groups at one week after surgery (P ＞ 0.05). The above-mentioned adverse reactions were mostly grade Ⅰ-Ⅱ, and no serious adverse events related to the treatment drugs occurred. Conclusion Licartin combined with TACE for the treatment of patients with primary liver cancer is well tolerated and safe, but the efficacy needs further verification.
[1] 中华人民共和国卫生部.原发性肝癌诊疗规范（2019年版）[J].肿瘤综合治疗电子杂志，2020，6（2）：55-85.
[2] Kim JY，Sinn DH，Gwak GY，et al. Transarterial chemoembolization versus resection for intermediate-stage（BCLC B）hepatocellular carcinoma [J]. Clin Mol Hepatol，2016， 22（2）：250-257.
[3] Yang B，Li CL，Guo WH，et al. Intra-arterial ethanol embolization augments response to TACE for treatment of HCC with portal venous tumor thrombus [J]. BMC cancer，2018，18（1）：1-10.
[4] Jonggi C，Danbi L，Ju HS，et al. Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma [J]. PLoS One，2020，15（3）：e0229696.
[5] Elshaarawy O，Gomaa A，Omar H，et al. Intermediate stage hepatocellular carcinoma：a summary review [J]. J Hepatocell Carcinoma，2019，6：105-117.
[6] Yang B， Liang J， Qu ZY，et al. Transarterial strategies for the treatment of unresectable hepatocellular carcinoma：A systematic review [J]. PLoS One，2020，15（2）：e0227475.
[7] da Costa AC，Sodergren M，Jayant K，et al. Radiofrequency combined with immunomodulation for hepatocellular carcinoma：State of the art and innovations [J]. World J Gastroenterol，2020，26（17）：2040-2048.
[8] Siracusano G，Tagliamonte M，Buonaguro L，et al. Cell Surface Proteins in Hepatocellular Carcinoma：From Bench to Bedside [J]. Vaccines，2020，8（1）：41-46.
[9] Landras A，Reger de Moura C，Jouenne F，et al. CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker [J]. Cancers，2019，11（11）：1803.
[10] Fan W，Wu Y，Lu M，et al. A meta-analysis of the effificacy and safety of iodine 131I metuximab Infusion combined with TACE for treatment of hepatocellular carcinoma [J]. Clin Res Hepatol Gas，2019，43（4）：451-459.
[11] Oken M，Creech R，Tormey D，et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group [J]. Am J Clin Oncol，1982，5（6）：649-655.
[12] Orloff MJ，Vaida F，Isenberg JI，et al. Child -Turcotte score versus MELD for prognosis in a randomized controlled trial of emergency treatment of bleeding esophageal varices in cirrhosis [J]. J Surg Res，2012，178（1）：139-146．
[13] Riccardo L，Josep ML. Modified RECIST（mRECIST）assessment for hepatocellular carcinoma [J]. Semin in Liver Dis，2010，30（1）：52-60.
[14] 皋文君，刘砚燕，袁长蓉.国际肿瘤化疗药物不良反应评价系统-通用不良反应术语标准4.0版[J].肿瘤，2012， 3（2）：142-144.
[15] Kume A，Nimura Y，Kamiya J，et al. Percutaneous ethanol injection via an artificially induced right hydrothorax for hepatocellular carcinomain the hepaticdome [J]. Cardiovasc Intervent Radiol，2003，26（6）：543-551.
[16] 王滨，徐辉，曹贵文，等.肝动脉化疗栓塞对肝癌肿瘤新生血管生成及血管内皮细胞生长因子表达的影响[J].中华放射学杂志，2005（2）：92-94.
[17] Nag S，DeHaan M，Scrnggs G，et al. Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy [J]. Int J Radiat Oncol Biol Phys，2006，64（3）：736-779.
[18] 许国辉，张智慧，李政文，等.131I肝癌单抗片段 HAb18F（ab）2灌注治疗原发性肝癌的临床研究[J].介入放射学杂志，2005，14（6）：596-598．
[19] He B，Mao C，Ru B，et al. Epitope mapping of metuximab on CD147 using phage display and molecular docking [J]. Comput Math Methods Med，2013，8（4），e983829.
[20] Chen ZN，Mi L，Xu J，et al. Targeting radioimmunotherapy of hepatocellular carcinoma with iodine（131I）metuximab injection：clinical phaseI/II trials [J]. Int J Radiat Oncol Biol Phys，2006，65（2）：435-444.
[21] Ma J，Wang JH. 131I-labeled-metuximab plus transarterial chemoembolizationin combination therapy for unresectable hepatocellular carcinoma：results from a multicenter phase IV clinical study [J]. Asian Pac J Cancer Prev，2015，16（17）：7441-7447.
[22] He Q，Lu WS，Liu Y，et al. 131I-labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma [J]. World J Gastroenterol，2013，19（47）：9104-9113.
[23] Wu L，Yang YF，Ge NJ，et al. Hepaticartery injection of 131I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma：a prospective nonrandomized study [J]. Eur J Nucl Med Mol Imaging，2012，39（8）：1306-1319.
[24] 秦文俊，徐细明.利卡汀联合肝动脉栓塞化疗治疗中晚期肝癌的效果及安全性的系统评价[J].中国医药导报，2016，13（25）：46-50.
[25] 余子牛，李家平，卢鸣剑，等.经肝动脉灌注利卡汀序贯联合TACE治疗不可切除肝细胞癌的近期疗效与安全性分析[J].临床放射学杂志，2016，35（6）：929-933.
[26] 王会香，高洪波，张晓勇.利卡汀联合 TACE 治疗原发性肝癌患者焦虑状况的影响因素分析[J].护理实践与研究，2012，9（14）：137-139.
[27] 梁建丽，夏苏娇，朱萍.利卡汀联合肝动脉化疗栓塞术治疗原发性肝癌的观察与护理[J].海峡药学，2010，22（4）：109-111.
[28] 王根柱，李保东.利卡汀辅助肝动脉栓塞化疗治疗中晚期肝癌的可行性分析[J].海峡药学，2017，6（29）：184-185.
[29] Wu L，Yang YF，Ge NJ，et al. Hepaticarterial iodine-131-labeled metuximab injection combined with chemoembolization for unresectable hepatocellular carcinoma：interim safety and survival data from 110 patients [J]. Cancer Biother Radiopharm，2010，25（5）：657-663.
[30] Li Z，Zhou JX，Ren JZ，et al. Clinical value of 131I metuximab infusion combined with TACE for treatment of patients with post-intervention relapse of mid or advanced stage hepatocellular carcinoma [J]. Zhonghua Gan Zang Bing Za Zhi，2013，21（10）：728-733.
[31] Guo X，Sun T，Li S. An analysis of outcomes of treatment of primary liver cancer with 131I-metuximab infusion combined with TACE [J]. Zhong Guo Xian Dai Yi Xue Za Zhi，2011，21（10）：1026-1033.
2020, Vol. 17 
京公网安备 11010502046598号